Search research articles
Contact Us
Filters
Showing results (71-80 of 84) with videos related to
Page
of 9
Sort By:
The Lancet. Oncology
|
September 9, 2017
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Beatrice Seddon, Sandra J Strauss, Jeremy Whelan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 2, 2014
Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial
Marie-Cécile Le Deley, Michael Paulussen, Ian Lewis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 15, 2015
Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial
Henk van den Berg, Michael Paulussen, Gwénaël Le Teuff, et al.
JMIR Research Protocols
|
October 2, 2019
Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy
Gabriele Calaminus, Meriel Jenney, Lars Hjorth, et al.
The Lancet. Oncology
|
March 13, 2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Ian Judson, Jaap Verweij, Hans Gelderblom, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 23, 2014
Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study
Anna Maria Frezza, Marilena Cesari, Daniel Baumhoer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2015
Ewing Sarcoma: Current Management and Future Approaches Through Collaboration
Nathalie Gaspar, Douglas S Hawkins, Uta Dirksen, et al.
The Lancet. Oncology
|
October 4, 2015
The expanding role of primary care in cancer control
Greg Rubin, Annette Berendsen, S Michael Crawford, et al.
Nature Communications
|
May 29, 2021
Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden
Peter Peneder, Adrian M Stütz, Didier Surdez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 7, 2018
High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008
Jeremy Whelan, Marie-Cecile Le Deley, Uta Dirksen, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 84) with videos related to
Sort By:
Page
of 9
The Lancet. Oncology
|
September 9, 2017
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Beatrice Seddon, Sandra J Strauss, Jeremy Whelan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 2, 2014
Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial
Marie-Cécile Le Deley, Michael Paulussen, Ian Lewis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 15, 2015
Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial
Henk van den Berg, Michael Paulussen, Gwénaël Le Teuff, et al.
JMIR Research Protocols
|
October 2, 2019
Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy
Gabriele Calaminus, Meriel Jenney, Lars Hjorth, et al.
The Lancet. Oncology
|
March 13, 2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Ian Judson, Jaap Verweij, Hans Gelderblom, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 23, 2014
Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study
Anna Maria Frezza, Marilena Cesari, Daniel Baumhoer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2015
Ewing Sarcoma: Current Management and Future Approaches Through Collaboration
Nathalie Gaspar, Douglas S Hawkins, Uta Dirksen, et al.
The Lancet. Oncology
|
October 4, 2015
The expanding role of primary care in cancer control
Greg Rubin, Annette Berendsen, S Michael Crawford, et al.
Nature Communications
|
May 29, 2021
Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden
Peter Peneder, Adrian M Stütz, Didier Surdez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 7, 2018
High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008
Jeremy Whelan, Marie-Cecile Le Deley, Uta Dirksen, et al.
Page
of 9